Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
A

How I Treat Newly Diagnosed MM in 2020: Is VTD Superior to VCD? Is D-VTd Beneficial for PFS/OS in Transplant-Eligible Disease? Should We Use Thalidomide Maintenance After ASCT?

By 7th Eurasian Hematology Oncology Summit FEATURING Angelo Maiolino
By 7th Eurasian Hematology Oncology Summit FEATURING Angelo Maiolino
0 views
December 9, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Myeloma
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With b…

Feat. E. Terpos
14:20
7th Eurasian Hematology Oncology Summit

How I Treat Newly Diagnosed MM in 2020: Is VTD Superior to VCD? Is D…

Feat. A. Maiolino
16:17
7th Eurasian Hematology Oncology Summit

VRd, KRd and IRd in R/R MM: Real World vs. Clinical Trial Data

Feat. A. Chari
15:49
7th Eurasian Hematology Oncology Summit

2020 Updates on Maintenance Therapies in MM: Should We Consider Doub…

Feat. M. Gavriatopoulou